Summit Therapeutics PLC (SMMT)
Healthcare
Biotechnology
13.00 $
-3.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Summit Therapeutics PLC (SMMT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 19.1% of the shares are freely tradable; institutional investors hold 15.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
15.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
83.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
19.1%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
24.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
798Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Baker Bros Advisors LP | 4.56 | 36,391,063 | +0.0 | 03/31/2026 |
| FMR Inc | 1.36 | 10,853,199 | -18.8 | 03/31/2026 |
| BlackRock Inc | 1.21 | 9,653,758 | +3.1 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 1.04 | 8,277,859 | -11.7 | 03/31/2026 |
| State Street Corp | 0.88 | 7,028,160 | +5.9 | 03/31/2026 |
| Vanguard Capital Management, LLC | 0.72 | 5,711,802 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 0.66 | 5,233,252 | +0.0 | 03/31/2026 |
| UBS Group AG | 0.46 | 3,680,315 | +322.7 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 0.92 | 7,301,322 | -1.0 | 07/30/2026 |
| Vanguard Morn Total Stk Mkt Idx Investor | 0.46 | 3,708,976 | -0.6 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.